IPCA Laboratories

IPCA Laboratories Receivables

The Accounts Receivable of IPCA Laboratories (IPCALAB.NS) as of Oct 30, 2026 is 18.89 B INR. In the previous year, Accounts Receivable was 17.04 B INR — a change of 10.84% (higher).

Receivables

18.89 BINR

YoY

10.84%

Last updated:

Accounts Receivable of IPCA Laboratories is 2025 18.89 B INR. Accounts Receivable of IPCA Laboratories was 2024 17.04 B INR. It decreases by 10.84% higher compared to the previous year.

The IPCA Laboratories Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
6.06 B INR
Jan 1, 2019
6.84 B INR
Jan 1, 2020
8.99 B INR
Jan 1, 2021
8.16 B INR
Jan 1, 2022
9.18 B INR
Jan 1, 2023
10.34 B INR
Jan 1, 2024
17.04 B INR
Jan 1, 2025
18.89 B INR
The IPCA Laboratories Receivables history
YEARReceivablesYoY
18.89 BINR+10.84%
17.04 BINR+64.89%
10.34 BINR+12.60%
9.18 BINR+12.54%
8.16 BINR-9.30%
8.99 BINR+31.48%
6.84 BINR+12.82%
6.06 BINR+18.42%
5.12 BINR+13.73%
4.50 BINR-29.50%
6.39 BINR+42.07%
4.50 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Accounts Receivable of IPCA Laboratories is 18.89 B INR in 2025.

Accounts Receivable of IPCA Laboratories changed from 17.04 B INR to 18.89 B INR, representing a 10.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — IPCA Laboratories

All Key Metrics — IPCA Laboratories